iVAC-CLL01: Patient-individualized Peptide Vaccination After First Line Therapy of CLL

Phase 2 Completed 56 enrolled University Hospital Tuebingen Katharinenhospital Stuttgart · collab Klinikum Stuttgart · collab Marienhospital Stuttgart · collab Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF) · collab

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The aim of this study is to induce a peptide-specific immune response in CLL patients by multi-peptide vaccination with a patient-individualized peptide cocktail.

Timeline

Start: 2016-10-05
Primary completion: 2022-09-30
Completion: 2022-11-18

Publications

Heitmann JS, Jung S, Wacker M, Maringer Y, Nelde A, Bauer J, Denk M, Hoenisch-Gravel N, Richter M, Oezbek MT, Dubbelaar ML, Bilich T, Pumptow M, Martus P, Illerhaus G, Denzlinger C, Steinbach F, Aulitzky WE, Muller MR, Dorfel D, Rammensee HG, Salih HR, Walz JS. Warehouse-based, immunopeptidome-guided design of personalised peptide vaccines shows feasibility in clinical trial evaluation in CLL patients. Front Immunol. 2024 Nov 26;15:1482715. doi: 10.3389/fimmu.2024.1482715. eCollection 2024.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	NY-ESO-1	Protein / enzyme biologic	300 ug	Subcutaneous
Background	Imiquimod	Other / unclassified	—	Topical

iVAC-CLL01: Patient-individualized Peptide Vaccination After First Line Therapy of CLL

Summary

Timeline

Publications

Drugs

Indications